Elranatamab: A novel B-cell maturation T-cell engager
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis Group
2026-12-01
|
| Edice: | Human Vaccines & Immunotherapeutics |
| Témata: | |
| On-line přístup: | https://www.tandfonline.com/doi/10.1080/21645515.2026.2694852 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|